Wave Life Sciences (WVE) SVP sells shares under trading plan agreement

Q: What does the Wave Life Sciences (WVE) Form 4 filing report?

The Form 4 reports that executive Chris Francis exercised 9,375 share options and sold ordinary shares of Wave Life Sciences Ltd. on January 2, 2026 .

Q: How many options did Chris Francis exercise and at what price?

Chris Francis exercised 9,375 share options at an exercise price of $3.14 per share, receiving an equal number of ordinary shares .

Q: How many Wave Life Sciences shares did Chris Francis sell and at what prices?

He sold 8,080 ordinary shares at a weighted-average price of $15.92 per share and 1,295 ordinary shares at a weighted-average price of $16.70 per share, each across multiple transactions within disclosed price ranges.

Q: What is Chris Francis’s role at Wave Life Sciences?

According to the filing remarks, Chris Francis is SVP, Corporate Development, Head of Emerging Areas at Wave Life Sciences Ltd.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Wave Life Sciences Ltd. executive Chris Francis reported an option exercise and share sales in a Form 4. On January 2, 2026, Francis exercised 9,375 share options at an exercise price of $3.14 per share, receiving the same number of ordinary shares. On the same day, he sold 8,080 ordinary shares at a weighted-average price of $15.92 per share and 1,295 ordinary shares at a weighted-average price of $16.70 per share, in multiple transactions within disclosed price ranges. After these transactions, Francis directly owned 25,000 ordinary shares. The filing notes that these fully vested options and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 5, 2025.

Insider Trade Summary

Net Seller: 9,375 shares ($150,260)

Net Sell 4 txns

Insider Francis Chris

Role See Remarks

Sold 9,375 shs ($150K)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	9,375	$0.00	--
Exercise	Ordinary Shares	9,375	$3.14	$29K
Sale	Ordinary Shares	8,080	$15.92	$129K
Sale	Ordinary Shares	1,295	$16.70	$22K

Holdings After Transaction: Share Option (right to buy) — 0 shares (Direct); Ordinary Shares — 34,375 shares (Direct)

Footnotes (1)

The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. These share options are fully vested. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.56 to $16.54 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.61 to $16.79 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

01/06/2026 - 09:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Francis Chris

(Last)

(First)

(Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE

02138

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	01/02/2026		M⁽¹⁾		9,375	A	$3.14	34,375	D
Ordinary Shares	01/02/2026		S⁽¹⁾		8,080	D	$15.92⁽³⁾	26,295	D
Ordinary Shares	01/02/2026		S⁽¹⁾		1,295	D	$16.7⁽⁴⁾	25,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$3.14	01/02/2026		M			9,375	⁽²⁾	01/01/2032	Ordinary Shares	9,375	$0.00	0	D

Explanation of Responses:

1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

2. These share options are fully vested.

3. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.56 to $16.54 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

4. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.61 to $16.79 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Remarks:

SVP, Corporate Development, Head of Emerging Areas

	/s/ Chris Francis	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What does the Wave Life Sciences (WVE) Form 4 filing report?

The Form 4 reports that executive Chris Francis exercised 9,375 share options and sold ordinary shares of Wave Life Sciences Ltd. on January 2, 2026.

How many options did Chris Francis exercise and at what price?

Chris Francis exercised 9,375 share options at an exercise price of $3.14 per share, receiving an equal number of ordinary shares.

How many Wave Life Sciences shares did Chris Francis sell and at what prices?

He sold 8,080 ordinary shares at a weighted-average price of $15.92 per share and 1,295 ordinary shares at a weighted-average price of $16.70 per share, each across multiple transactions within disclosed price ranges.

How many Wave Life Sciences shares does Chris Francis own after these transactions?

Following the reported transactions, Chris Francis directly owned 25,000 ordinary shares of Wave Life Sciences Ltd.

Was the Wave Life Sciences insider transaction made under a Rule 10b5-1 plan?

Yes. The filing states that the option exercise and related sales were effected under a Rule 10b5-1 trading plan adopted by Chris Francis on August 5, 2025.

What is Chris Francis’s role at Wave Life Sciences?

According to the filing remarks, Chris Francis is SVP, Corporate Development, Head of Emerging Areas at Wave Life Sciences Ltd.